Cellectricon Signs Collaboration Agreement with AstraZeneca
News May 04, 2006
The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.
"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery," says Dr. Mattias Karlsson, VP Research & Development at Cellectricon.
"The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."
"We believe the Nanoflow system has the potential to expedite our efforts in ion channel drug discovery and we look forward to working in collaboration with Cellectricon," says Dr. Christer Nordstedt, VP Discovery Research Area CNS & Pain Control.
3-D Printed Sugar Scaffolds Offer Sweet Solution for Tissue EngineeringNews
University of Illinois engineers built a 3-D printer that offers a sweet solution to making detailed structures that commercial 3-D printers can’t: Rather than a layer-upon-layer solid shell, it produces a delicate network of thin ribbons of hardened isomalt, the type of sugar alcohol used to make throat lozenges.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018